Genmab AS Valuation
| GMAB Stock | USD 20.51 0.55 2.76% |
At this time, the firm appears to be undervalued. Genmab AS retains a regular Real Value of $24.63 per share. The prevalent price of the firm is $20.51. Our model calculates the value of Genmab AS from evaluating the firm fundamentals such as Return On Equity of 0.23, return on asset of 0.11, and Current Valuation of 10.15 B as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Genmab AS's price fluctuation is not too volatile at this time. Calculation of the real value of Genmab AS is based on 3 months time horizon. Increasing Genmab AS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Genmab AS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genmab Stock. However, Genmab AS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.51 | Real 24.63 | Hype 20.51 | Naive 16.95 |
The real value of Genmab Stock, also known as its intrinsic value, is the underlying worth of Genmab AS Company, which is reflected in its stock price. It is based on Genmab AS's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genmab AS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genmab AS helps investors to forecast how Genmab stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genmab AS more accurately as focusing exclusively on Genmab AS's fundamentals will not take into account other important factors: Genmab AS Total Value Analysis
Genmab AS is currently forecasted to have valuation of 10.15 B with market capitalization of 13.07 B, debt of 1.03 B, and cash on hands of 21.61 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Genmab AS fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.15 B | 13.07 B | 1.03 B | 21.61 B |
Genmab AS Investor Information
The book value of the company was currently reported as 577.54. The company has Price/Earnings To Growth (PEG) ratio of 1.12. Genmab AS had not issued any dividends in recent years. The entity had 5:1 split on the 1st of May 2018. Based on the key indicators related to Genmab AS's liquidity, profitability, solvency, and operating efficiency, Genmab AS is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Genmab AS Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genmab AS has an asset utilization ratio of 46.99 percent. This suggests that the Company is making $0.47 for each dollar of assets. An increasing asset utilization means that Genmab AS is more efficient with each dollar of assets it utilizes for everyday operations.Genmab AS Ownership Allocation
Genmab AS has a total of 635.5 Million outstanding shares. Roughly 90.68 (percent) of Genmab AS outstanding shares are held by general public with 0.007 % owned by insiders and only 9.31 pct. by outside corporations. On February 11, 2025, Representative Josh Gottheimer of US Congress acquired under $15k worth of Genmab AS's common stock.Genmab AS Profitability Analysis
The company reported the previous year's revenue of 21.53 B. Net Income was 7.84 B with profit before overhead, payroll, taxes, and interest of 20.54 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Genmab AS's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Genmab AS and how it compares across the competition.
About Genmab AS Valuation
The stock valuation mechanism determines Genmab AS's current worth on a weekly basis. Our valuation model uses a comparative analysis of Genmab AS. We calculate exposure to Genmab AS's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genmab AS's related companies.Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on NASDAQ Exchange in the United States.
Genmab AS Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 64.6 M | |
| Quarterly Earnings Growth Y O Y | 4.634 | |
| Forward Price Earnings | 11.7925 |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |